异种移植
免疫抑制
经济短缺
CD154
医学
移植
肾
肾移植
重症监护医学
内科学
生物
CD40
哲学
细胞毒性T细胞
体外
政府(语言学)
生物化学
语言学
作者
A. Joseph Tector,Andrew Adams,Matt Tector
出处
期刊:Kidney360
[Lippincott Williams & Wilkins]
日期:2022-12-18
卷期号:4 (2): 278-284
标识
DOI:10.34067/kid.0007152021
摘要
Renal transplantation is the preferred treatment of ESRD, but the shortage of suitable donor kidneys from the cadaver pool means that many patients with ESRD will not receive a kidney transplant. Xenotransplantation has long represented a solution to the kidney shortage, but the occurrence of antibody-mediated rejection has precluded its clinical development. Developments in: somatic cell nuclear transfer in pigs, gene editing tools have led to the creation of new donor pigs with greatly improved crossmatches to patients. In addition, improvements in preclinical kidney xenotransplant survival using new anti-CD40/CD154 based immunosuppression, have pushed xenotransplantation to the point where it is reasonable to consider initiating a clinical trial to evaluate this potential therapy in patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI